Paxlovid

Amit Dagar, once a trusted statistician for pharmaceutical behemoth Pfizer Inc (NYSE: PFE), and Atul Bhiwapurkar, his close business ally, now find themselves mired in allegations that could see their financial futures irreparably tarnished. In this week's installment of Financial Crime...

Pfizer, Inc. (NYSE: PFE) is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States. What Happened: Pfizer will invest an incremental $120 million at its Kalamazoo, Michigan facility to augment production of Paxlovid, the pharma giant said in a...

Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA...

Pfizer Inc (NYSE: PFE) applied for emergency use authorization of its oral antiviral Paxlovid last week after reporting data showing that it was 89% effective at preventing hospitalization or death in at-risk people. Pfizer CEO Albert Bourla is confident that the oral antiviral will not...